Both in Pharmaceuticals
ARS Pharmaceuticals vs DiaMedica Therapeutics
Over the past year SPRY returned −54.7% and DMAC returned +18.7%; their daily moves had a correlation of 0.27.
SPRY −54.7% DMAC +18.7%Growth of $1, one year, split-adjusted
| Metric | SPRY | DMAC |
|---|---|---|
| Price | $4.40 | $8.20 |
| Market cap | $437.6M | $442.2M |
| Today | +6.54% | −1.44% |
| 1 month | −25.3% | +28.3% |
| 6 months | −43.7% | +23.5% |
| Year to date | −62.2% | +3.0% |
| 1 year | −55.1% | +18.2% |
| Revenue growth (YoY) | +114.2% | — |
| Gross margin | 61.8% | — |
| Net margin | −185.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 3.7× | — |
| Net cash | -$27.8M | $43.5M |
| Dividend yield | — | — |
| Volatility (60d) | 70.0% | 43.2% |
| Short % of float | 47.1% | 22.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).